PharmaTher Holdings Ltd

As of February 28, 2026, PharmaTher Holdings Ltd carries a market capitalization of 6.83M, placing it among publicly traded companies globally. Its enterprise value stands at 5.96M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

PharmaTher Holdings Ltd's next confirmed earnings release is scheduled for October 28, 2026.

As of February 28, 2026, PharmaTher Holdings Ltd has 91.02M shares outstanding.

These figures are as of February 28, 2026.

As of February 28, 2026, PharmaTher Holdings Ltd maintains a current ratio of 1.64, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended February 28, 2026, PharmaTher Holdings Ltd posted a negative return on equity (ROE) of -99.83, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -73.72, reflecting losses generated across the asset base.

As of the close on October 22, 2026, PharmaTher Holdings Ltd's stock has declined approximately 57.69% over the past 52 weeks. The 50-day moving average sits at 0.06, while the 200-day moving average is 0.08.

Over the twelve months ended February 28, 2026, PharmaTher Holdings Ltd generated - - in revenue and converted that into -1.06M in net income, yielding earnings per share of -0.01. EBITDA reached -1.12M, while operating income came in at -1.12M.

These figures are as of February 28, 2026. Total book value stands at 533,527.00, with working capital of 340,714.00 providing operational flexibility.

PharmaTher Holdings Ltd produced -639,713.00 in operating cash flow over the twelve months ended February 28, 2026.

These figures cover the twelve months ended February 28, 2026. Free cash flow yield is negative at -9.44: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -3.66, meaning PharmaTher Holdings Ltd raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of February 28, 2026, PharmaTher Holdings Ltd has an Altman Z-Score of -12.46, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.